The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Open accessAbstract
BACKGROUND: p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC). METHODS: p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end point was objective response (complete or partial response) according to independent central review. Key secondary end points included duration of response, disease control (defined as complete response, partial response, or stable disease), progression-free survival, overall survival, and safety. Exploratory biomarkers were evaluated for their association with response to sotorasib therapy. RESULTS: . CONCLUSIONS: p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sotorasib response rate in colorectal cancer is lower than that in NSCLC (7).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, in a preliminary analysis, the response rate of MRTX849 in NSCLC patients harboring mutations in both KRAS G12C and KEAP1 was reduced compared to the response rate in KRAS G12C , KEAP1 WT patients [13, 14].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, KRAS G12C inhibition produces substantially different outcomes in NSCLC and CRC, largely due to lineage-specific feedback regulation [23,26,27,28,32].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sotorasib and adagrasib, two prominent members of this class, were effective at halting the growth of G12C-mutant cancer cells in 2-dimensional, 3-dimensional, and xenograft models, clearing the path for clinical trials [48,49,50,51].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [49]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but all patients eventually developed therapeutic resistance, limiting long-term survival.19”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have revealed that sotorasib demonstrates satisfactory efficacy in patients with non–small cell lung cancer, with a satisfactory response rate [12, 13].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, patients with KRASG12C-mutated non–small cell lung cancer achieved a durable clinical benefit from sotorasib, the first approved KRASG12C mutant-selective inhibitor, whereas patients with CRC bearing the same mutation responded less to the same treatment [12].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotorasib was associated with an objective response rate of 37.1% and a median progression-free survival of 6.8 months among patients with NSCLC14 and a response rate of 7.1% among those with colorectal cancer.10”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, AMG510 treatment in patients with KRASG12C-driven NSCLC achieved a response rate of over 30%,18,19”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“For sotorasib, an overall response rate (ORR) of 7.1–9.7% was observed in patients with advanced CRC, compared to 32.2–37.1% in those with advanced NSCLC (Table 1) [26, 46, 47].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, some patients selected for these trials may have preexisting multidrug resistance (9, 37, 74), which could contribute to treatment failure.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, sotorasib has been shown to strongly inhibit phosphorylation of ERK protein in KRASG12C cells, thereby suppressing cell proliferation.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [53]
In the citing paper
“Sotorasib specifically and irreversibly inhibits KRASG12C by binding to GDP and locking KRAS in an inactive state.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [53]
In the citing paper
“The approval of Lumakras, an Amgen-developed drug, in May 2021 for treating NSCLC patients with KRASG12C mutations marks a significant milestone in KRAS-targeting drug discovery.53”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [53]
In the citing paper
“Some preclinical and clinical studies have reported that some drugs could reverse resistance induced by RAS, such as sotorasib, dasatinib and metformin [155,156,157].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [157]
In the citing paper
“In terms of gastrointestinal adverse effects frequently observed in other KRAS G12C inhibitors, 11,12,28 the incidence was generally lower in garsorasib (diarrhea at 11.5%, nausea at 7.7%, and no vomiting reported), compared to those reported of other KRAS G12C inhibitors (diarrhea at 31.7-69%, nausea at 19-78%, and vomiting at 7.9-58%).”
In the citing paper
“Both also showed antitumor activity against KRASG12C-mutated tumors in early-phase clinical trials (20), leading to the accelerated approval of sotorasib by the FDA in May 2021 and conditional marketing authorization by the European Commission in January 2022.”
In the citing paper
“Single-agent JDQ443 demonstrated antitumor activity in both panels, with deeper responses in NSCLC than colorectal cancer (Fig. 4A vs. 4E; Supplementary Table S7), consistent with reported clinical findings for other single-agent KRASG12C inhibitors in these indications (20, 21, 25, 33).”
In the citing paper
“Some of these inhibitors have proven efficacy in patients with KRASG12C-mutant cancers and have become practice changing.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“The phase II portion of CodeBreaK 100, which involved 124 evaluable patients with previously treated advanced-stage KRASG12C-mutant NSCLC, demonstrated an ORR of 37.1%, a median duration of response (DoR) of 11.1 months, median PFS of 6.8 months and median OS of 12.5 months67. These impressive results led to the 2021 FDA accelerated approval of sotorasib for this indication.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“However, the data on KRASG12C inhibitors, which have advanced the furthest in development and are entering clinical practice, emphasize that these agents are far from curative67.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [67]
In the citing paper
“Despite this success, disease progression occurs in many patients4,5,7, with development of resistance to KRASG12Ci recapitulated in preclinical studies9–11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [7]
In the citing paper
“Preclinical and clinical studies, however, have demonstrated that cancers lose sensitivity to KRASG12Ci and re-establish RAS-MAPK signaling through multiple mechanisms, including increased activation of mutant or wild-type (WT) RAS and/or gain of upstream/downstream bypass events1,7,9,10,13,14.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [7]
In the citing paper
“sotorasib (AMG 510) and adagrasib (MRTX849) have demonstrated robust efficacy with objective response rates of 37% and 45%, and disease control rates of 81% and 96%, respectively (20, 23–25).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [24]
In the citing paper
“Exploratory correlative analyses from the KRYSTAL-1 and CodeBreaK 100 trials in this context suggest higher response rates for single agent adagrasib (64% vs 45%) and sotorasib (50% vs 39%) among patients whose tumors harbored an STK11 co-mutation, versus the entire treatment cohort (24, 25).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [24]
In the citing paper
“While KRASG12C inhibitors deliver clinical benefit, all patients who achieved an objective response ultimately progressed on treatment with sotorasib in a Phase II study (24).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [24]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“In the updated analysis, the overall response rate remained at 37.1% although one of the partial responses converted to a complete response.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The updated analysis provided the first report of overall survival for NSCLC patients treated with a selective KRAS G12C inhibitor.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Per recent subgroup analyses of the Phase II NSCLC cohort from CodeBreaK 100, patients appear to derive benefit after PD1/PD-L1 checkpoint inhibition, including the application of the checkpoint inhibitor within 3 months of sotorasib initiation31.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The vast majority of patients (115 of 126) received prior PD-1/PD-L1 checkpoint inhibition and the response rate was 36.3% (vs. 37.1% in the overall population) and median overall survival was 12.0 months (versus 12.5 months in the overall population).”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Patients whom have had checkpoint therapy within 3 months had overall response of 34.4% and median overall survival of 11.7 months, compared to 39.7% and not evaluable in patients that had more than 3 months between checkpoint inhibition and sotorasib.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The vast majority of patients (115 of 126) received prior PD-1/PD-L1 checkpoint inhibition and the response rate was 36.3% (vs. 37.1% in the overall population) and median overall survival was 12.0 months (versus 12.5 months in the overall population).”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“These data may indicate that prior immune therapy does not meaningfully negatively impact the activity of sotorasib, suggesting a possible combination approach may be further explored given non-overlapping mechanisms of action.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“The vast majority of patients (115 of 126) received prior PD-1/PD-L1 checkpoint inhibition and the response rate was 36.3% (vs. 37.1% in the overall population) and median overall survival was 12.0 months (versus 12.5 months in the overall population).”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Recent overall survival data has been favorable with an overall survival of 12.5 months including second and third line and beyond patients receiving benefit.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [31]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [12]
In the citing paper
“Median PFS was 6.8 months and median survival was 12.5 months (Table 2).”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [94]
In the citing paper
“The NSCLC cohort included 126 patients, 81% of whom had received prior platinum-based chemotherapy and PD(L)1 inhibitor therapy. With a median follow-up of 15.3 months, the response rate was 37.1%; 80.6% of patients achieved disease control.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [94]
In the citing paper
“While ORR was 50% in those with mutated STK11 and wild-type KEAP1, it was only 23% when both KEAP1 and STK11 were mutated and 14% when KEAP1 was mutated with wild-type STK11 (Table 3).”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [94]
In the citing paper
“Nevertheless, drugs again other KRAS mutations in codons 12, 13 and 61 still remain to be developed [87].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [87]
In the citing paper
“Sotorasib (AMG-510) (Table 1) was the first selective KRAS(G12C) inhibitor to enter clinical trials in 2018 and was developed by Amgen, building on discoveries from a partnership with Carmot Therapeutics in which a custom library of small molecules that covalently bind cysteine were screened against KRAS(G12C)93.”
From Advances in covalent drug discovery (2022) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,004
Ishida, M., Iwasaku, M., Doi, T., Ishikawa, T., Tachibana, Y., Sawada, R., Ogura, Y., Kawachi, H., Katayama, Y., Nishioka, N., et al. (2024) · Cancer Science · doi:10.1111/cas.16130 · Cited by 24
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu, Y., Lankadasari, M. B., Rosiene, J. A., Johnson, K. E., Zhou, J., Bapat, S., Chow-Tsang, L.-F., Tian, H., Mastrogiacomo, B., He, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101777 · Cited by 25
Self-citationShembrey, C., Yang, R., Casan, J. M. L., Hu, W., Chen, H., Singh, G. J., Sadras, T., Prasad, K., Shortt, J., Johnstone, R. W., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl0731 · Cited by 26
Tanaka, N., & Ebi, H. (2024) · Cancer Science · doi:10.1111/cas.16441 · Cited by 26
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025) · Cancers · doi:10.3390/cancers17030353 · Cited by 27
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Shaverdashvili, K., & Burns, T. F. (2025) · Cancer · doi:10.1002/cncr.35783 · Cited by 25
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
Cho, B. C., Lü, S., Lee, M. A., Song, Z., Park, J., Lim, S. M., Li, Z., Zhao, J., Richardson, G. E., Zhang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03688-6 · Cited by 24
Disrupted molecular glue complex drives RAS inhibitor resistance
Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 43
Self-citationNovel targeted therapies for advanced non-small lung cancer
Abughanimeh, O. K. M., Kaur, A., Osta, B. E. E., & Ganti, A. K. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.03.003 · Cited by 26
Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis
Liu, X., Hai, Y., Dong, J., Xu, L., Hou, W., Su, J., Ren, W., & Liu, D. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5447 · Cited by 26
Ayasun, R., Saridogan, T., Gaber, O., & Şahin, İ. H. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.001 · Cited by 22
Eliminating oncogenic RAS: back to the future at the drawing board
Steffen, C. L., Kaya, P., Schaffner‐Reckinger, E., & Abankwa, D. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221343 · Cited by 23
Proteolysis targeting chimeras in non-small cell lung cancer
Hagopian, G. G., Grant, C., & Nagasaka, M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102561 · Cited by 26
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 25
The choreography of protein kinase PDK1 and its diverse substrate dance partners
Leroux, A. E., & Biondi, R. M. (2023) · Biochemical Journal · doi:10.1042/bcj20220396 · Cited by 25
Passiglia, F., Reale, M. L., Russo, G. L., Pasello, G., Minuti, G., Bulotta, A., Galetta, D., Pelizzari, G., Sini, C., Bria, E., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107444 · Cited by 24
Ernst, S. M., van Marion, R., Atmodimedjo, P. N., de Jonge, E., Mathijssen, R. H. J., Paats, M. S., de Bruijn, P., Koolen, S. L., von der Thüsen, J. H., Aerts, J. G. J. V., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.04.007 · Cited by 24
An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth
Kaya, P., Schaffner‐Reckinger, E., Manoharan, G. B., Vukić, V., Kiriazis, A., Ledda, M., Renedo, M. B., Pavic, K., Gaigneaux, A., Glaab, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02129 · Cited by 22
Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.03.006 · Cited by 23
Alsaed, B., Bobik, N., Laitinen, H. K., Nandikonda, T., Ilonen, I., & Haikala, H. M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10272-4 · Cited by 25
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 25
Guaitoli, G., Bertolini, F., Bettelli, S. R., Manfredini, S., Maur, M., Trudu, L., Aramini, B., Masciale, V., Grisendi, G., Dominici, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312867 · Cited by 25
Rosell, R., Aguilar, A., Pedraz‐Valdunciel, C., & CHAIB-OUKADOUR, I. (2021) · Nature Cancer · doi:10.1038/s43018-021-00289-3 · Cited by 23
Choudhury, Y., Tan, M., Shi, J., Tee, A. K. H., Ngeow, K. C., Poh, J., Goh, R. R., & Mong, J. C. Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.758464 · Cited by 23
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
Ganguly, A., & Yoo, E. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.011 · Cited by 24
Moon, H. (2022) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2022.30.e9 · Cited by 23
Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?
Andreani, C., Bartolacci, C., & Scaglioni, P. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923915 · Cited by 26
Zhuang, H., Fan, J., Li, M., Zhang, H., Yang, X., Lin, L., Lu, S., Wang, Q., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915512 · Cited by 23
Koster, K., Appenzeller, C., Lauber, A., Früh, M., & Schmid, S. (2022) · Case Reports in Oncology · doi:10.1159/000525341 · Cited by 24
The Gut Microbiome and Pancreatic Cancer Development and Treatment
Attebury, H., & Daley, D. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000647 · Cited by 24
Desai, A. P., Rakshit, S., Bansal, R., Ashara, Y. P., Potter, A. L., Manochakian, R., Lou, Y., Zhao, Y., Ernani, V., Savvides, P., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100743 · Cited by 23
A patent review of MAPK inhibitors (2018 – present)
Wydra, V. R., Ditzinger, R., Seidler, N. J., Hacker, F. W., & Laufer, S. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2242584 · Cited by 24
Boeschen, M., Kuhn, C. K., Wirtz, H. R. W., Seyfarth, H., Frille, A., Lordick, F., Hacker, U. T., Obeck, U., Stiller, M., Bläker, H., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107361 · Cited by 28
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 25
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 24
Tee, W.-V., Lim, S. J. M., & Berezovsky, I. N. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01043 · Cited by 23
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
Yu, L., Yang, R., Long, Z., Tao, Q., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1451230 · Cited by 23
Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
Sunaga, N., Miura, Y., Kasahara, N., & Sakurai, R. (2021) · Cancers · doi:10.3390/cancers13235956 · Cited by 23
New developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 23
Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 22
Self-citationPotent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
Ooki, A., Osumi, H., Fukuda, K., & Yamaguchi, K. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10121-2 · Cited by 24
Ottaiano, A., Sabbatino, F., Perri, F., Cascella, M., Sirica, R., Patrone, R., Capuozzo, M., Savarese, G., Ianniello, M., Petrillo, N., et al. (2023) · Cancers · doi:10.3390/cancers15143579 · Cited by 23
The promise and peril of KRAS G12C inhibitors
Moore, A. R., & Malek, S. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.011 · Cited by 22
Argentiero, A., Andriano, A., Caradonna, I. C., Martino, G. D., & Desantis, V. (2024) · Cancers · doi:10.3390/cancers16132438 · Cited by 21
Tumour-agnostic kinase inhibitors
Adashek, J. J., Nikanjam, M., & Kurzrock, R. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01147-y · Cited by 21
Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., Lund‐Iversen, M., Brustugun, O. T., Førde, D., Paulsen, E., et al. (2021) · Cancers · doi:10.3390/cancers13174294 · Cited by 22
Novoplansky, O., Jagadeeshan, S., Regev, O., Menashe, I., & Elkabets, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.838911 · Cited by 23
Terrenato, I., Ercolani, C., Benedetto, A. D., Gallo, E., Melucci, E., Casini, B., Rollo, F., Palange, A., Visca, P., Pescarmona, E. O., et al. (2022) · Cancers · doi:10.3390/cancers14122971 · Cited by 21
Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
Huynh, M. V., Parsonage, D., Forshaw, T. E., Chirasani, V. R., Hobbs, G. A., Wu, H., Lee, J., Furdui, C. M., Poole, L. B., & Campbell, S. L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102186 · Cited by 21
Elkrief, A., Odintsov, I., Markov, V., Caeser, R., Sobczuk, P., Tischfield, S. E., Bhanot, U. K., Vanderbilt, C., Cheng, E. H., Drilon, A. E. D. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.007 · Cited by 23
Targeted therapy for rare lung cancers: Status, challenges, and prospects
Wang, C., Yuan, X., & Xue, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.007 · Cited by 21
Gadgeel, S. M., Miao, J., Riess, J. W., Moon, J., Mack, P. C., Gerstner, G. J., Burns, T. F., Taj, A., Akerley, W., Dragnev, K. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3947 · Cited by 22
Hsu, R. C., Benjamin, D. J., & Nagasaka, M. (2023) · Cancers · doi:10.3390/cancers15143561 · Cited by 21
Brambs, C., Horn, L., Hiller, R., Krücken, I., Braun, C., Christmann, C., Monecke, A., & Höhn, A. K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05306-9 · Cited by 22
Macaya, I., Román, M., Welch, C., Entrialgo‐Cadierno, R., Salmón, M., Santos, A., Feliu, I., Kovalski, J. R., López, I., Rodríguez‐Remírez, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41828-z · Cited by 22
Hu, S., Han, Y., Tan, T.-Y., Chen, H., Gao, J.-W., Wang, L., Yang, M., Zhao, L., Wang, Y., Ding, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167874 · Cited by 22
Chen, Q., Lin, W., Zhou, X.-X., Cao, Z., Feng, X., Gao, Y., & He, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107060 · Cited by 22
Puyalto, A., Rodríguez‐Remírez, M., López, I., Macaya, I., Guruceaga, E., Olmedo, M., Vilalta, A., Welch, C., Sandiego, S., Vicent, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01991-3 · Cited by 21
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216692 · Cited by 20
Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions
Nishio, H., Matsuda, R., Iwata, T., & Yamagami, W. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae019 · Cited by 20
Hochmair, M. J., Vermaelen, K. Y., Mountzios, G., Carcereny, E., Dooms, C., Lee, S., Mórocz, É., Kato, T., Ciuleanu, T., Dy, G. K., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114204 · Cited by 20
Self-citationChen, M., Huang, Y., Jiang, S., & Ke, C. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107966 · Cited by 21
The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression
Kang, J., Gallucci, S., Pan, J., Oakhill, J. S., & Sanij, E. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1449543 · Cited by 21
Chao, A., Huang, C., Yu, W., Lin, C., Lin, H., Chao, A., Lin, C., Chou, H., Huang, K.-G., Huang, H.-J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13125-5 · Cited by 21
Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Krupa, K., Fudalej, M. M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17152453 · Cited by 21
Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
Wang, Y., Zhong, B., Xu, C., Zhan, D., Zhao, S., Wu, H., Liu, M., Lan, X., Cai, D., Ding, Q., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106080 · Cited by 19
Crystal Structure of an i‐Motif from the HRAS Oncogene Promoter
Li, S. K., Jordan, D., Lin, L. Y., McCarthy, S. E., Schneekloth, J. S., & Yatsunyk, L. A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301666 · Cited by 20
Lang, D., Ritzberger, L., Rambousek, V., Horner, A., Wass, R. E., Akbari, K., Kaiser, B., Kronbichler, J., Lamprecht, B., & Gabriel, M. (2021) · Cancers · doi:10.3390/cancers13236096 · Cited by 20
Strohbehn, G. W., Lichter, A. S., & Ratain, M. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02049 · Cited by 20
Li, X., Ye, J., Wang, J., Quan, Z., Li, G., Ma, W., Zhang, M., Yang, W., Wang, J., Ma, T., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265715 · Cited by 21
Cortiana, V., Abbas, R. H., Chorya, H. P., Gambill, J. L., Mahendru, D., Park, C. H., & Leyfman, Y. (2024) · Cancers · doi:10.3390/cancers16132329 · Cited by 19
Šereš, M., Spacayova, K., Sulová, Z., Špaldová, J., Breier, A., & Pavlíková, L. (2025) · Cancers · doi:10.3390/cancers17020248 · Cited by 28
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
Frisch, A., Martin, E., Kim, S. Y., Riess, J. W., Sen, T., & Karim, N. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf153 · Cited by 24
Rahimi, A., Khibech, O., Benabbou, A., Merzouki, M., Bouhrim, M., Al-Zharani, M. M., Nasr, F. A., Qurtam, A. A., Abadi, S., Challioui, A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081110 · Cited by 19
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers
Jeong, J., Hausmann, S., Dong, H., Szczepski, K., Flores, N. M., Gonzalez, A. G., Shi, L., Lu, X., Lempiäinen, J. K., Jakab, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09299-y · Cited by 22
Targeting the “undruggable” RAS with biologics
Whaby, M., Khan, I., & O’Bryan, J. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.006 · Cited by 19
Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Cheng, C.-Y., Chen, C., & Wu, C. (2022) · Life · doi:10.3390/life12060829 · Cited by 19
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Malone, C. F., Kim, M., Alexe, G., Engel, K. L., Forman, A. B., Robichaud, A. L., Conway, A. S., Goodale, A. B., Meyer, A., Khalid, D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4309 · Cited by 19
Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
Peng, L., Guo, J., Kong, L., Huang, Y., Tang, N., Zhang, J., Wang, M., He, X., Li, Z., Peng, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070761 · Cited by 24
Bertaglia, V., Morelli, A. M., Solinas, C., Aiello, M. M., Manunta, S., Denaro, N., Tampellini, M., Scartozzi, M., & Novello, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103954 · Cited by 20
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 21
Khan, H. Y., Nagasaka, M., Aboukameel, A., Alkhalili, O. A., Uddin, M. H., Bannoura, S. F., Mzannar, Y., Azar, I. H., Beal, E. W., Tobon, M. E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0251 · Cited by 18
Han, L., Jiang, Y., Shi, M., Gan, L., Wu, Z., Xue, M., Zhu, Y., Xiong, C., Wang, T., Lin, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04702-6 · Cited by 19
A narrative review of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer
Hsu, R. C., & Benjamin, D. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252652 · Cited by 19
Kazi, A., Ranjan, A., Vasantha Kumar, M. V., Agianian, B., Chavez, M. G., Vudatha, V., Wang, R., Vangipurapu, R., Chen, L., Kennedy, P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0222 · Cited by 16
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction
Vaccaro, K., Allen, J., Whitfield, T. W., Maoz, A., Reeves, S., Velarde, J., Yang, D., Meglan, A., Ribeiro, J., Blandin, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169315 · Cited by 19
Decoding the functional impact of the cancer genome through protein–protein interactions
Fu, H., Mo, X., & Ivanov, A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00784-6 · Cited by 22
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Tammaccaro, S. L., Prigent, P., Le Bail, J.-C., Dos-Santos, O., Dassencourt, L., Eskandar, M., Buzy, A., Venier, O., Guillemot, J.-C., Veeranagouda, Y., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040553 · Cited by 18
Zhang, F., Wang, B., Wu, M., Zhang, L., & Ji, M. Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1509173 · Cited by 20
Chen, Y., Jiang, L., Zhang, L., Chi, H., & Wang, Q. (2025) · Discover Oncology · doi:10.1007/s12672-025-02169-z · Cited by 17
Pancreatic cancer in 2025: Have we found a solution?
Tonini, V., & Zanni, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i43.111433 · Cited by 23
Targeting Mutated KRAS Genes to Treat Solid Tumours
Krishnan, T., Roberts‐Thomson, R., Broadbridge, V. T., & Price, T. J. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00564-0 · Cited by 18
Self-citationGrohé, C., Blau, W. J., Gleiber, W., Haas, S., Hammerschmidt, S., Krüger, S., Müller-Huesmann, H., Schulze, M., Wehler, T., Atz, J., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2021.12.010 · Cited by 18
Pîrlog, R., & Călin, G. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci161454 · Cited by 18
Targeting protein conformations with small molecules to control protein complexes
Zacharioudakis, E., & Gavathiotis, E. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.07.002 · Cited by 19
Personalized treatment for patients with lung cancer
Schüler, M., Bölükbas, S., Darwiche, K., Theegarten, D., Herrmann, K., & Stuschke, M. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0012 · Cited by 20
Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer
Zhao, J., DiGiacomo, V., Ferreras-Gutiérrez, M., Dastjerdi, S., de Opakua, A. I., Park, J., Luebbers, A., Chen, Q., Beeler, A. B., Blanco, F. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213140120 · Cited by 18
Levis, M., Gastino, A., Giorgi, G. D., Mantovani, C., Bironzo, P., Mangherini, L., Ricci, A. A., Ricardi, U., Cassoni, P., & Bertero, L. (2023) · Cancers · doi:10.3390/cancers15184622 · Cited by 19
Schmidt, V. F., Kapp, F., Goldann, C., Huthmann, L., Cucuruz, B., Brill, R., Vielsmeier, V., Seebauer, C. T., Michel, A., Seidensticker, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033287 · Cited by 18
Metadata
- Authors
- Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., Kato, T., Curioni-Fontecedro, A., Sacher, A., Spira, A., Ramalingam, S. S., Takahashi, T., Besse, B., Anderson, A., Ang, A., Tran, Q., Mather, O., Henary, H., Ngarmchamnanrith, G., Friberg, G., Velcheti, V., & Govindan, R.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (F.S.), and U.S. Oncology Research, the Woodlands (A. Spira) — both in Texas; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (B.T.L.) and Thoracic Medical Oncology, Perlmutter Cancer Center, New York University (V.V.), New York, and Roswell Park Cancer Institute, Buffalo (G.K.D.) — all in New York; the Queen Elizabeth Hospital and University of Adelaide, Woodville, SA, Australia (T.J.P.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), the West German Cancer Center, University Hospital Essen, University Duisburg–Essen, Essen (M.S.), and the German Cancer Consortium, Heidelberg (M.S.) — all in Germany; the Early Phase Trials and Sarcoma Units, Bergonie Cancer Institute, Bordeaux (A.I.), and Gustave Roussy Institute, Villejuif (F.B., B.B.) — both in France; Fox Chase Cancer Center, Philadelphia (H.B....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-24
- Volume
- 384
- Issue
- 25
- Pages
- 2371-2381
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9116274
- OpenAlex
- W3172081492
- Semantic Scholar
- 3c89f24ad219bec52684f03b8df3c5d8feb81a72
- Cited by
- 1,849
- References
- 39
- Citations by year
- 2026: 317 · 2025: 348 · 2024: 398 · 2023: 382 · 2022: 319 · 2021: 84
- FWCI
- 192.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sotorasib, non-small cell lung cancer, KRAS inhibitors, advanced solid tumors, objective response, progression-free survival, biomarkers, drug safety
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Pyridines, Pyrimidines, Biomarkers, Proto-Oncogene Proteins p21(ras), B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
